Elucidation of the underlying mechanisms of action for Ra-223 will soon expand its clinical utility with respect to improved patient selection and integrated bone-targeted therapies.
Sue-Hwa Lin, PhD
Advertisement
Articles by Sue-Hwa Lin, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Anticipated Data and Practice-Changing Trials: An ASCO 2026 Breast Cancer Preview
2
FDA Approves Pivekimab Sunirine in Rare Hematologic Malignancy
3
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial
4
Toripalimab Regimen Improves EFS, MPR Rate in Stage II/III NSCLC Trial
5